Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

Tanespimycin is the First Hsp90 Inhibitor to Enter Registration Trials

HAYWARD, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that it has successfully reached a binding agreement with the U.S. Food and Drug Administration (FDA) on the design of its TIME-1 clinical trial, a pivotal Phase 3 trial of its Hsp90 inhibitor tanespimycin as a treatment for patients with multiple myeloma. Through the FDA's Special Protocol Assessment (SPA) process, Kosan and the FDA have reached agreement on overall protocol design, primary efficacy endpoints and data analysis as well as aspects of expected labeling if the data from the pivotal trial are supportive and tanespimycin is approved by the FDA. This pivotal Phase 3 protocol, as well as the overall development program, have also completed the "Scientific Advice" process with the centralized European Medicines Agency (EMEA).

Kosan's registration program for tanespimycin, called Tanespimycin in Myeloma Evaluation or TIME, has been initiated and includes two clinical trials: TIME-1 and TIME-2. TIME-1 is a pivotal Phase 3 trial to be conducted in a first-relapse patient population. TIME-1 will evaluate the clinical benefit of adding tanespimycin to bortezomib and compare these results to those seen with single-agent bortezomib. The Special Protocol Assessment Kosan has completed applies to the TIME-1 trial. TIME-2, which is designed to be supportive of the TIME-1 trial, is a Phase 2/3 trial in patients with relapsed-refractory disease. The TIME-2 trial also has the potential to support registration in the relapsed-refractory setting. Kosan has initiated the TIME-2 trial, which is enrolling patients, and expects to init
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... and NEW YORK , October 1, 2014 ... Organization (CRO) and service provider for the medical industries, announced today ... offices in New York City . genae Americas ... is strategically centered in one of the highest concentrations ... said Philippe Kassab , President at genae Americas. "The expansion ...
(Date:10/1/2014)... , Oct. 1, 2014  Express Scripts (NASDAQ: ... available 2015 Express Scripts Medicare ® Prescription Drug ... featuring Walgreens (NYSE: WAG ) (NASDAQ: ... choice and clinical support  for their Medicare dollars. ... Medicare Value or Choice plans ...
(Date:10/1/2014)... 2014  CVS Health is thanking its 26,000 pharmacists ... changing the way health care is delivered to increase ... retail pharmacies, mail service pharmacies and specialty pharmacies nationwide.  ... name to CVS Health to reflect our broader health ... needed to shape the future of health," said ...
Breaking Medicine Technology:genae Opens Offices in New York City 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3
... Announces Positive Data in Animal Models of ... /PRNewswire-FirstCall/ -- Callisto,Pharmaceuticals, Inc. , a developer ... cancer and other major health threats, announced,today ... compound currently being developed for the treatment,of ...
... Journal of Cell Science Shows ONCONASE Uptake in,Cells ... 2007 /PRNewswire-FirstCall/ --,Alfacell Corporation today announced that European ... to enter,cells. , Published in the Journal of ... studies conducted at the University of Girona in,Spain ...
Cached Medicine Technology:Callisto Intends to Move Guanilib into Clinical Trials in,Ulcerative Colitis 2Callisto Intends to Move Guanilib into Clinical Trials in,Ulcerative Colitis 3Callisto Intends to Move Guanilib into Clinical Trials in,Ulcerative Colitis 4Researchers Identify Intracellular Pathway of Alfacell's Onconase 2Researchers Identify Intracellular Pathway of Alfacell's Onconase 3
(Date:10/1/2014)... brain of a rat and a robot could revolutionise ... leading robotics researcher. , Dr Michael Milford from ... uses new computer algorithms to enable robots to navigate ... is a very Frankenstein type of project," Dr Milford ... together because we,re taking the eyes of a human ...
(Date:10/1/2014)... suggests the adage that encourages people to keep their ... it comes to exercise. When walking, staying focused on ... it appear shorter and help people walk there faster, ... technique to walking while looking around the environment naturally, ... exercise. , "People are less interested in exercise if ...
(Date:10/1/2014)... 01, 2014 Bedros Keuilian is not ... Camp fitness boot camps, he’s also considered the leading ... with sold out business summits, a line of high-demand ... to a recent Spike TV reality show to his ... is the time for personal trainers and fitness business ...
(Date:10/1/2014)... and ATLANTA (PRWEB) October 01, 2014 ... security executive networking and relationship-marketing firm, announced ... Information Security Executive® and Project of the ... top-ranking decision makers representing organizations in financial ... Projects include large-scale technology endeavors that address ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Beverly Hills ... Kathleen Mojas is celebrating 20 years of private practice ... hundreds of people to achieve greater joy and fulfillment ... list of warning signs and suggestions for anyone who ... Mojas explains: “Believe it or not, it’s not ...
Breaking Medicine News(10 mins):Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3
... , , JACKSONVILLE, Fla., ... network, today announced the expansion of its existing partnership with ... include secure real-time eligibility and benefits transactions at no charge ... relationship between Availity and WellCare for health care claims transactions, ...
... FORT LAUDERDALE, Fla., Aug. 25 OmniComm Systems, Inc. ... data capture (EDC) solutions for clinical trials, announced today ... Pleiad, Inc., a Cambridge, Massachusetts based Contract Research Organization ... eClinical services to its customers. Pleiad,s investment will provide ...
... , , LOUISVILLE, Colo., Aug. ... Plastic and Reconstructive Surgery Journal , the official journal ... been clinically proven to be a safe and effective treatment ... University demonstrated VASER Lipo to be an enhanced fat removal ...
... Serrated colorectal polyps include the subgroups hyperplastic polyps, sessile ... adenomas. Recent studies have found that serrated polyps share ... to the hypothesis that serrated polyps can be precursors ... to cancer sequence. These cancers tend to arise in ...
... , , , INDIANAPOLIS , ... its selection as one of LATINA Style magazine,s "Top Twelve Companies ... in the magazine,s 50 Report. More than 800 companies were considered ... Style magazine is an acknowledgment that our mission to improve the ...
... say , TUESDAY, Aug. 25 (HealthDay News) -- A ... tumors has been identified by German researchers. , The ... cancer and compared them with healthy breast tissue. The ... of GLI1 (glioma-associated oncogene homolog 1) protein tended to ...
Cached Medicine News:Health News:Availity Provides Real-Time Access to WellCare 2Health News:Pleiad Devices Selects OmniComm Systems as their eClinical Solutions Provider 2Health News:Pleiad Devices Selects OmniComm Systems as their eClinical Solutions Provider 3Health News:New Study Reveals VASER(R) Lipo to be the New Standard of Care for Body Contouring and Fat Transfer Procedures 2Health News:New Study Reveals VASER(R) Lipo to be the New Standard of Care for Body Contouring and Fat Transfer Procedures 3Health News:Reinterpretation of proximal colon polyps called hyperplastic in 2001 2Health News:WellPoint Named a Top Place to Work by LATINA Style Magazine 2Health News:WellPoint Named a Top Place to Work by LATINA Style Magazine 3Health News:Protein May Identify Deadlier Breast Cancer 2
... High performance Tecoflex stents that save inventory, ... Stents accommodate ureteral lengths from 22 cm ... allows the Quadra-Coil to glide over any ... These stents provide ease of placement and ...
... drainage from the ureteropelvic junction to the ... ease of placement and patient compliance. The ... repositioning and ease of removal. AQ® is ... when activated, attracts and holds water and ...
The CMV IgM enzyme immunoassay is for the qualitative detection of antibodies to cytomegalovirus. The CMV IgM assay is primarily indicated for the detection of early or recent infection....
The Shandon Sequenza uses the Shandon Coverplate system which ensures consistency and excellent staining quality. , , ,Allows the user to perform large immunostaining runs (up to 50 slides/run...
Medicine Products: